Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP4297 maintenance therapy in ovarian cancer
NCT04169997Phase 3Active, not recruiting
- Sponsor
- IMPACT Therapeutics
- Start
- Dec 2019
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer comparing IMP4297 with Placebo (2 arms). Primary endpoint: Progression-Free Survival at 42 months. Started Dec 2019; status: active, not recruiting.
02
Drugs
senaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04169997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169997.